Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapies for rare endocrine diseases and endocrine-related tumors. Its lead candidate, Paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 agonist being studied in Phase 3 trials for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. The company is also advancing Atumelnant, an oral nonpeptide ACTH receptor antagonist that has completed a Phase 1 study for conditions linked to excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease, as well as CRN09682, a nonpeptide drug conjugate for SST2-positive solid tumors. Additional programs include PTH receptor antagonists, thyroid-stimulating hormone receptor antagonists, an SST3 agonist program, and oral GLP-1 and GLP-1-related candidates for obesity. Crinetics also has development and commercialization agreements in Japan for Paltusotine and with Cellular Longevity for CRN01941. Founded in 2008, the company is headquartered in San Diego, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.